Cargando…
Cardiovascular Effects of Pharmacological Targeting of Sphingosine Kinase 1
High blood pressure is a risk factor for cardiovascular diseases. Ang II (angiotensin II), a key pro-hypertensive hormone, mediates target organ consequences such as endothelial dysfunction and cardiac hypertrophy. S1P (sphingosine-1-phosphate), produced by Sphk1 (sphingosine kinase 1), plays a pivo...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott, Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7055939/ https://www.ncbi.nlm.nih.gov/pubmed/31838904 http://dx.doi.org/10.1161/HYPERTENSIONAHA.119.13450 |
_version_ | 1783503452555444224 |
---|---|
author | Józefczuk, Ewelina Nosalski, Ryszard Saju, Blessy Crespo, Eva Szczepaniak, Piotr Guzik, Tomasz Jan Siedlinski, Mateusz |
author_facet | Józefczuk, Ewelina Nosalski, Ryszard Saju, Blessy Crespo, Eva Szczepaniak, Piotr Guzik, Tomasz Jan Siedlinski, Mateusz |
author_sort | Józefczuk, Ewelina |
collection | PubMed |
description | High blood pressure is a risk factor for cardiovascular diseases. Ang II (angiotensin II), a key pro-hypertensive hormone, mediates target organ consequences such as endothelial dysfunction and cardiac hypertrophy. S1P (sphingosine-1-phosphate), produced by Sphk1 (sphingosine kinase 1), plays a pivotal role in the pathogenesis of hypertension and downstream organ damage, as it controls vascular tone and regulates cardiac remodeling. Accordingly, we aimed to examine if pharmacological inhibition of Sphk1 using selective inhibitor PF543 can represent a useful vasoprotective and cardioprotective anti-hypertensive strategy in vivo. PF543 was administered intraperitoneally throughout a 14-day Ang II-infusion in C57BL6/J male mice. Pharmacological inhibition of Sphk1 improved endothelial function of arteries of hypertensive mice that could be mediated via decrease in eNOS (endothelial nitric oxide synthase) phosphorylation at T495. This effect was independent of blood pressure. Importantly, PF543 also reduced cardiac hypertrophy (heart to body weight ratio, 5.6±0.2 versus 6.4±0.1 versus 5.9±0.2 mg/g; P<0.05 for Sham, Ang II+placebo, and Ang II+PF543-treated mice, respectively). Mass spectrometry revealed that PF543 elevated cardiac sphingosine, that is, Sphk1 substrate, content in vivo. Mechanistically, RNA-Seq indicated a decreased expression of cardiac genes involved in actin/integrin organization, S1pr1 signaling, and tissue remodeling. Indeed, downregulation of Rock1 (Rho-associated coiled-coil containing protein kinase 1), Stat3 (signal transducer and activator of transcription 3), PKC (protein kinase C), and ERK1/2 (extracellular signal-regulated kinases 1/2) level/phosphorylation by PF543 was observed. In summary, pharmacological inhibition of Sphk1 partially protects against Ang II–induced cardiac hypertrophy and endothelial dysfunction. Therefore, it may represent a promising target for harnessing residual cardiovascular risk in hypertension. |
format | Online Article Text |
id | pubmed-7055939 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Lippincott, Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-70559392020-03-19 Cardiovascular Effects of Pharmacological Targeting of Sphingosine Kinase 1 Józefczuk, Ewelina Nosalski, Ryszard Saju, Blessy Crespo, Eva Szczepaniak, Piotr Guzik, Tomasz Jan Siedlinski, Mateusz Hypertension Original Articles High blood pressure is a risk factor for cardiovascular diseases. Ang II (angiotensin II), a key pro-hypertensive hormone, mediates target organ consequences such as endothelial dysfunction and cardiac hypertrophy. S1P (sphingosine-1-phosphate), produced by Sphk1 (sphingosine kinase 1), plays a pivotal role in the pathogenesis of hypertension and downstream organ damage, as it controls vascular tone and regulates cardiac remodeling. Accordingly, we aimed to examine if pharmacological inhibition of Sphk1 using selective inhibitor PF543 can represent a useful vasoprotective and cardioprotective anti-hypertensive strategy in vivo. PF543 was administered intraperitoneally throughout a 14-day Ang II-infusion in C57BL6/J male mice. Pharmacological inhibition of Sphk1 improved endothelial function of arteries of hypertensive mice that could be mediated via decrease in eNOS (endothelial nitric oxide synthase) phosphorylation at T495. This effect was independent of blood pressure. Importantly, PF543 also reduced cardiac hypertrophy (heart to body weight ratio, 5.6±0.2 versus 6.4±0.1 versus 5.9±0.2 mg/g; P<0.05 for Sham, Ang II+placebo, and Ang II+PF543-treated mice, respectively). Mass spectrometry revealed that PF543 elevated cardiac sphingosine, that is, Sphk1 substrate, content in vivo. Mechanistically, RNA-Seq indicated a decreased expression of cardiac genes involved in actin/integrin organization, S1pr1 signaling, and tissue remodeling. Indeed, downregulation of Rock1 (Rho-associated coiled-coil containing protein kinase 1), Stat3 (signal transducer and activator of transcription 3), PKC (protein kinase C), and ERK1/2 (extracellular signal-regulated kinases 1/2) level/phosphorylation by PF543 was observed. In summary, pharmacological inhibition of Sphk1 partially protects against Ang II–induced cardiac hypertrophy and endothelial dysfunction. Therefore, it may represent a promising target for harnessing residual cardiovascular risk in hypertension. Lippincott, Williams & Wilkins 2020-02 2019-12-16 /pmc/articles/PMC7055939/ /pubmed/31838904 http://dx.doi.org/10.1161/HYPERTENSIONAHA.119.13450 Text en © 2019 The Authors. Hypertension is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made. |
spellingShingle | Original Articles Józefczuk, Ewelina Nosalski, Ryszard Saju, Blessy Crespo, Eva Szczepaniak, Piotr Guzik, Tomasz Jan Siedlinski, Mateusz Cardiovascular Effects of Pharmacological Targeting of Sphingosine Kinase 1 |
title | Cardiovascular Effects of Pharmacological Targeting of Sphingosine Kinase 1 |
title_full | Cardiovascular Effects of Pharmacological Targeting of Sphingosine Kinase 1 |
title_fullStr | Cardiovascular Effects of Pharmacological Targeting of Sphingosine Kinase 1 |
title_full_unstemmed | Cardiovascular Effects of Pharmacological Targeting of Sphingosine Kinase 1 |
title_short | Cardiovascular Effects of Pharmacological Targeting of Sphingosine Kinase 1 |
title_sort | cardiovascular effects of pharmacological targeting of sphingosine kinase 1 |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7055939/ https://www.ncbi.nlm.nih.gov/pubmed/31838904 http://dx.doi.org/10.1161/HYPERTENSIONAHA.119.13450 |
work_keys_str_mv | AT jozefczukewelina cardiovasculareffectsofpharmacologicaltargetingofsphingosinekinase1 AT nosalskiryszard cardiovasculareffectsofpharmacologicaltargetingofsphingosinekinase1 AT sajublessy cardiovasculareffectsofpharmacologicaltargetingofsphingosinekinase1 AT crespoeva cardiovasculareffectsofpharmacologicaltargetingofsphingosinekinase1 AT szczepaniakpiotr cardiovasculareffectsofpharmacologicaltargetingofsphingosinekinase1 AT guziktomaszjan cardiovasculareffectsofpharmacologicaltargetingofsphingosinekinase1 AT siedlinskimateusz cardiovasculareffectsofpharmacologicaltargetingofsphingosinekinase1 |